SPECIAL FEATURES

Highlights of This Issue 7435

CCR Translations

7437 Jumping the Barrier: Modeling Drug Penetration across the Blood–Brain Barrier
Cody J. Peer, Cindy H. Chau, and William D. Figg
See related article, p. 7454

Statistics in CCR

7440 Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making
Christina Yap, Lucinda J. Billingham, Ying Kuen Cheung, Charlie Craddock, and John O’Quigley

CCR Drug Updates

7448 FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen
Amy Barone, Dow-Chung Chi, Marc R. Theoret, Huanyu Chen, Kun He, Dubravka Kufrin, Whitney S. Helms, Sriram Subramaniam, Hong Zhao, Anuja Patel, Kirsten B. Goldberg, Patricia Keegan, and Richard Pazdur

CANCER THERAPY: CLINICAL

7454 Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients: IVIVE–PBPK Modeling Approach
Jing Li, Jannet Wu, Xun Bao, Norissa Honea, Youming Xie, Seongho Kim, Alex Sparreboom, and Nader Sanai
See related commentary, p. 7437

7467 A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

7474 Immune Activation in Early-Stage Non–small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
John S. Yi, Neal Ready, Patrick Healy, Chelsee Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, Jeffrey Clarke, Jeffrey Crawford, Betty Tong, David Harpole, Thomas A. D’Amico, Frances McSherry, Frank Dunphy, Shannon J. McCall, Jared D. Christensen, Xiaofei Wang, and Kent I. Weinhold

7483 A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Marjorie G. Zauderer, Anne S. Tsao, Tao Diao, Katherine Panagias, W. Victoria Lai, Andreas Rimmer, Valerie W. Ruch, Prasad S. Adusumilli, Michelle S. Ginsberg, Daniel Gomez, David Rice, Reza Mehran, David A. Scheinberg, and Lee M. Krug

7490 A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Antonio Jimeno, Michael Gordon, Rashmi Chugh, Wells Messersmith, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Shailaja Uttamsingh, Rainer K. Brachmann, and David C. Smith

7498 Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

PERSONALIZED MEDICINE AND IMAGING

7512 Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
<table>
<thead>
<tr>
<th>Page</th>
<th>Title and Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7521</td>
<td>Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer</td>
</tr>
<tr>
<td>7531</td>
<td>In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior</td>
</tr>
<tr>
<td>7543</td>
<td>Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy</td>
</tr>
<tr>
<td>7550</td>
<td>Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium</td>
</tr>
<tr>
<td>7558</td>
<td>Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia</td>
</tr>
<tr>
<td>7569</td>
<td>CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors</td>
</tr>
<tr>
<td>7584</td>
<td>Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors</td>
</tr>
<tr>
<td>7596</td>
<td>Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer</td>
</tr>
<tr>
<td>7608</td>
<td>Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action</td>
</tr>
</tbody>
</table>
**BIOLOGY OF HUMAN TUMORS**

**7621**  
A Complex Network of Tumor Microenvironment in Human High-Grade Serum Ovarian Cancer  

**7633**  
The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma  

**7641**  
Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space  
Oliver Wood, James Clarke, Jeongmin Woo, Adal H. Mirza, Christopher H. Woelk, Gareth J. Thomas, Pandurangan Vijayanand, Emma King, and Christian H. Ottensmeier

**7650**  
Transmembrane and Coiled-Coil Domain 1 Impairs the AKT Signaling Pathway in Urinary Bladder Urothelial Carcinoma: A Characterization of a Tumor Suppressor  
Chien-Feng Li, Wen-Ren Wu, Ti-Chun Chan, Yu-Hui Wang, Lih-Ren Chen, Wen-Jeng Wu, Bi-Wen Yeh, Shih-Shin Liang, and Yow-Ling Shiuie

**7664**  
Acknowledgment to Reviewers

---

**ABOUT THE COVER**

The cover shows a section of a HBCx-22 AR/ER+ breast cancer patient-derived xenograft. Immunohistochemical staining shows AR expression in both the cytoplasm and the nuclei. For details, see the article by Yu and colleagues on page 7608 of this issue.